Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04189445 · ClinicalTrials.gov registry record · Phase 2
Futibatinib in Patients With Specific FGFR Aberrations
A Phase 2 study, sponsored by Taiho Oncology.
- Terminated
- Registry status
- Phase 2
- Development phase
- 115
- Enrollment target
NCT04189445 is a Phase 2 study that was terminated before completion, run by Taiho Oncology. The registered enrollment target is 115 participants.
The verdict
NCT04189445, a Phase 2 study, was terminated before completion, sponsored by Taiho Oncology.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 115 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of futibatinib in patients with FGFR aberrations in 3 distinct cohorts. Patients will be enrolled into one of 3 cohorts: patients with advanced, metastatic or locally-advanced solid tumors harboring FGFR1-4 rearrangements (excluding primary brain tumors and intrahepatic cholangiocarcinoma \[iCCA\]); patients with gastric or gastro-esophageal junction (GEJ) cancer harboring FGFR2 amplification; and patients with myeloid or lymphoid neoplasms with FGFR1 rearrangements.
Interventions
- DRUG Futibatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2020-08-05 |
| Est. Completion | 2024-11-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04189445
The ClinicalTrials.gov registry entry for NCT04189445 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 115 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Taiho Oncology, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Futibatinib is the first listed.
NCT04189445 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04189445 about?
NCT04189445 is a clinical study titled "Futibatinib in Patients With Specific FGFR Aberrations". The purpose of this study is to evaluate the efficacy and safety of futibatinib in patients with FGFR aberrations in 3 distinct cohorts. Patients will be enrolled into one of 3 cohorts: patients with advanced, metastatic or locally-advanced solid tumors harboring FGFR1-4 rearrangements (excluding pr...
What is the current status of trial NCT04189445?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 115 participants. The study started on 2020-08-05. Estimated completion is 2024-11-11.
What interventions are being tested in trial NCT04189445?
The interventions under investigation include: Futibatinib (DRUG).
Who is sponsoring clinical trial NCT04189445?
This trial is sponsored by Taiho Oncology, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.